ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 67.3 | 58.4 | 72.8 |
| Other income | 0.1 | 0.2 | 0.5 |
| Total income | 67.4 | 58.6 | 73.2 |
| Profit before exceptional items & tax | -13.3 | -9.8 | 1.6 |
| Profit before tax | -13.3 | -9.8 | 1.6 |
| Net profit | -13.4 | -9.8 | 0.1 |
| Operating margin | -19.7% | -16.7% | 2.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -7.60% |
|---|
BSE results filing, NSE: MANGALAM. Figures extracted from the filing.
Mangalam Drugs and Organics Ltd: key numbers
- Share price
- ₹29.40
- Market cap
- ₹46.53 Cr
- Revenue (annual)
- ₹232.1 Cr
- Net profit (annual)
- ₹-44.40 Cr
- P/E (TTM)
- -1.2×Sector 43.8×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mangalam Drugs and Organics Ltd
All →Mangalam Drugs and Organics Q2 FY27 Results: Net Loss of ₹7.2 Cr, Loss Narrows
Mangalam Drugs and Organics Ltd reported revenue from operations of ₹79.4 Cr (+61.1% YoY) and a net loss of ₹7.2 Cr for Q2 FY27.
- Key figure
- Net loss ₹7.2 Cr
Mangalam Drugs and Organics Other Announcement
Mangalam Drugs & Organics Ltd has dispatched physical letters to shareholders without registered emails. These letters provide web-links to access the Annual Report for FY 2025-26.
Mangalam Drugs and Organics Management Change
Mangalam Drugs and Organics appointed Prabhakar Raghunath Zavar as Non-Executive Independent Director for 60 months, effective 15 September 2026. The disclosure covers a board-level appointment with a background profile and no monetary amount.
- Execution
- 60 months
Mangalam Drugs and Organics Board Meeting Date
Mangalam Drugs will hold a board meeting on 5 November 2026 to consider unaudited September 2026 quarter results. The agenda is proposed only, pending the meeting.
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs issued a postal ballot notice seeking approval to re-appoint Praveen Saxena as independent director for a second five-year term. Voting closes 17 June 2026.
Mangalam Drugs and Organics Debt & Borrowing: ₹1,557 Cr
Mangalam Drugs and Organics Limited has reported a default amounting to Rs.1,557.27 Crore. The company has submitted a restructuring proposal to its banks to manage the obligation.
- Value
- ₹1,557 Cr